Mar 2, 2017 by Brian Orelli, PhDWhy Puma Biotechnology Inc. Got Hammered TodayCompetition from rival Roche has the biotech trading lower.
Mar 1, 2017 by Brian Orelli, PhDWhy Amicus Therapeutics, Inc. Jumped Higher TodayThe biotech could benefit from a softer FDA.
Mar 1, 2017 by Brian Orelli, PhDIonis Pharmaceuticals Inc Turns a Profit With Other Drugmakers' MoneyCash from partners are paying the biotech's bills as its pipeline advances.
Mar 1, 2017 by Brian Orelli, PhDExelixis, Inc. Turns a Profit, but Don't Get Too ExcitedA couple of one-time events helped push the biotech into the black.
Feb 28, 2017 by Brian Orelli, PhDBetter Buy: bluebird bio, Inc. vs. Alnylam PharmaceuticalsA battle of knocked-down platform biotechs.
Feb 28, 2017 by Brian Orelli, PhDWhy Kindred Healthcare, Inc. Jumped Higher TodayBrighter days lie ahead for the healthcare services company.
Feb 27, 2017 by Brian Orelli, PhDWhy ImmunoGen, Inc. Skyrocketed Higher TodayThe biotech is set to present data next month.
Feb 25, 2017 by Brian Orelli, PhDBioMarin Pharmaceutical Inc. Logs a Combined BlockbusterIt only took four drugs to do it.
Feb 24, 2017 by Brian Orelli, PhDEmergent BioSolutions Inc Sets Its GoalThe biodefense expert thinks it can have $1 billion in revenue by 2020.
Feb 23, 2017 by Brian Orelli, PhDbluebird bio Inc Highlights a Data-Rich 2017Revenue and earnings aren't particularly important for the biotech at this stage.
Feb 22, 2017 by Brian Orelli, PhDMomenta Pharmaceuticals, Inc. Earnings Take a Back SeatThe attempted approval of the three-times-weekly version of Glatopa dominated the earnings conference call.
Feb 22, 2017 by Brian Orelli, PhDWhy Lantheus Holdings Inc Skyrocketed Higher TodaySolid fourth-quarter earnings, a positive outlook for 2017, and a new deal with GE Healthcare have the diagnostic-imaging company trading higher.
Feb 21, 2017 by Brian Orelli, PhDImmunoGen, Inc.: Waiting to Move FORWARDA clinical trial for the biotech's lead drug matters more than earnings.
Feb 21, 2017 by Brian Orelli, PhDWhy Momenta Pharmaceuticals, Inc. Shares Got Crushed TodayThe drugmaker announced a delay to approval of its three-times-weekly version of Glatopa.
Feb 15, 2017 by Brian Orelli, PhDWhy Genomic Health Inc. Jumped Higher TodayThe genetic-test maker revealed a solid fourth quarter, with the promise of more growth to come.
Feb 15, 2017 by Brian Orelli, PhDGenomic Health, Inc. Swings to a ProfitThe genetic-test maker gets into the black as it expands test sales outside of the U.S.
Feb 13, 2017 by Brian Orelli, PhDSeattle Genetics Earnings: Waiting on ECHELON2017 is looking like a transition year for the biotech.
Feb 10, 2017 by Brian Orelli, PhDWhy Ocular Therapeutix Inc Jumped Higher TodayAn analyst upgrade ahead of an FDA decision for its eye-pain medication sends shares higher.
Feb 9, 2017 by Brian Orelli, PhDAlnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig ItThe biotech used its fourth-quarter earnings to present plans to progress its pipeline, sending shares higher.
Feb 9, 2017 by Brian Orelli, PhDWhy OraSure Technologies, Inc. Leaped Higher TodayIt was an outstanding fourth quarter for the diagnostic test maker, and there's more to come this year.
